Cipla Ltd.

United States Food and Drugs Administration (USFDA) has concluded current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility in Bommasandra, Bengaluru. The inspection conducted from May 26, 2025 to May 30, 2025. 

On conclusion of the inspection, the company received one observation in Form 483. The company will work closely with the USFDA and remains committed to address the observation comprehensively within stipulated time. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.